The short version of anti-doping testing fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-08 and is reviewed periodically as new material appears.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water; stock solutions use organic solvent. |
| Storage | -20°C, desiccated, protected from light | Limits hydrolysis and photodegradation. |
| Analytical method | HPLC-UV/MS | Used for identity and purity assessment. |
| Synonyms | SR9009, Stenabolic | Naming varies by supplier. |
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Carnation Evaporated Milk (now owned by Nestlé and licensed to Smuckers in Canada) Dairy Isle (Canada by ADL) PET Evaporated Milk (now owned by Smuckers) Magnolia evaporated milk - (now produced by Eagle Family Foods ) Viking Melk (Norway) - invented by Olav Johan Sopp in 1891, a Nestlé brand since 1897 F&N Evaporated Milk California Farms Evaporated Milk Rainbow Milk, a brand of Royal Friesland Foods Nordmilch AG (Now DMK Deutsches Milchkontor) - Germany Jerzee Evaporated Milk (purchased in 2006 from Diehl Food Products) O-AT-KA Evaporated Milk Ferdi Evaporated Milk (Malaysia) Vitalait Evaporated Milk (Senegal) Luna Evaporated Milk (Saudi Arabia) Gloria Evaporated Milk (Peru)
The cell-extrinsic hallmarks of FLS in RA are: promotes osteoclastogenesis and bone erosion, contributes to cartilage degradation, induces synovial angiogenesis, and recruits and stimulates immune cells.
== Toxicity == The short-term lethal dose of melamine is on a par with common table salt, with an LD50 of more than 3 grams per kilogram of bodyweight. U.S. Food and Drug Administration (FDA) scientists explained that when melamine and cyanuric acid are absorbed into the bloodstream, they concentrate and interact in the urine-filled renal tubules, then crystallize and form large numbers of round, yellow crystals, which in turn block and damage the renal cells that line the tubes, causing the kidneys to malfunction and lead to kidney stones, kidney failure, and death. Signs of melamine toxicity can include irritability, blood in the urine, little to no urine, symptoms of kidney infection, or high blood pressure. The European Union set a standard for acceptable human consumption (tolerable daily intake or TDI) of melamine at 0.2 mg per kilogram of body mass (previously 0.5 mg/kg), Canada declared a limit of 0.35 mg/kg, and the US FDA's limit was put at 0.063 mg/kg (previously 0.63 mg/kg). The World Health Organization's food safety director estimated that the amount of melamine a person could stand per day without incurring a bigger health risk, the TDI, was 0.2 mg per kilogram of body mass. Toxicity of melamine can be mediated by intestinal microbiota. In culture, Raoultella terrigena, which rarely colonizes mammalian intestines, was shown to convert melamine to cyanuric acid directly. Rats colonized by R. terrigena showed greater melamine-induced kidney damage compared to those not colonized.
Sources: en.wikipedia.org
Lysis: This step involves breaking open the cells to release the DNA. For example, in the case of bacterial cells, a solution of detergent and salt (such as SDS) can be used to disrupt the cell membrane and release the DNA. For plant and animal cells, mechanical or enzymatic methods are often used. Precipitation: Once the DNA is released, proteins and other contaminants must be removed. This is typically done by adding a precipitating agent, such as alcohol (such as ethanol or isopropanol), or a salt (such as ammonium acetate). The DNA will form a pellet at the bottom of the solution, while the contaminants will remain in the liquid. Purification: After the DNA is precipitated, it is usually further purified by using column-based methods. For example, silica-based spin columns can be used to bind the DNA, while contaminants are washed away. Alternatively, a centrifugation step can be used to purify the DNA by spinning it down to the bottom of a tube. Concentration: Finally, the amount of DNA present is usually increased by removing any remaining liquid. This is typically done by using a vacuum centrifugation or a lyophilization (freeze-drying) step. Some variations on these steps may be used depending on the specific DNA extraction protocol. Additionally, some kits are commercially available that include reagents and protocols specifically tailored to a specific type of sample.
=== Health care === In 2019, Pritzker approved a tax on private insurance to help fund the state's Medicaid program. In August of that year, he signed legislation to eliminate the state's backlog of Medicaid applications, which as of March 15, 2019, included 112,000 that remained unprocessed past the federal 45-day limit. According to data from the Illinois Department of Human Services, the backlog was eliminated as of June 2020. In August 2023, under provisions of Illinois House Bill 2189 (the Access to Afford Insulin Act), Pritzker signed legislation capping insurance holders' out-of-pocket price of insulin at $35 for a 30-day supply. In July 2024, Pritzker signed bills allowing Illinois to spend $10 million to purchase medical debt from creditors, known as the Medical Debt Relief Pilot Program, under the Illinois Department of Healthcare and Family Services. The program was created to eliminate nearly $1 billion in medical debt for 340,000 low-income state residents. In February 2025, Pritzker announced that approximately 270,000 Illinoisans' medical debt, totaling $345 million, had been erased under the program. On April 22, 2025, United States Secretary of Health and Human Services Robert F. Kennedy Jr. announced a plan to use government data to help determine the causes of autism. In response, Pritzker signed an executive order that made Illinois the first state to block the federal government from collecting personal health data related to autism. In 2025, Pritzker signed Illinois House Bill 1697, the Prescription Drug Affordability Act.
== Further reading == Alexander, Mark, and John Sparry. Jump Commander: In Combat with the 82nd Airborne in World War II. Philadelphia: Casemate, 2010. ISBN 1-935149-28-8 OCLC 506253036 Angress, Werner T. Witness to the Storm: A Jewish Journey from Nazi Berlin to the 82nd Airborne, 1920–1945. Durham, NC: Miriam Angress, 2012. ISBN 1-4774-5701-1 OCLC 804824030 Anzuoni, Robert P. I'm the 82nd Airborne Division!: A History of the All American Division in World War II After Action Reports. Atglen, PA : Schiffer Publishing, 2005. ISBN 0-7643-2347-4 OCLC 62555533 Anzuoni, Robert P. The All American: An Illustrated History of the 82nd Airborne Division, 1917 to the Present. Atglen, PA: Schiffer Pub, 2001. ISBN 0-7643-1321-5 OCLC 49935879 Barry, Robert F. Power Pack: The Dominican Republic, 1965–1966. Portsmouth, Va: Messenger, 1965. OCLC 6655474 Baugh, James Emory. From Skies of Blue: My Experiences with the Eighty-Second Airborne During World War II. New York: iUniverse, 2003. ISBN 0-595-74982-8 OCLC 64584040 Breuer, William B. Drop Zone, Sicily: Allied Airborne Strike, July 1943. Novato, CA: Presidio, 1983. ISBN 0-89141-196-8 OCLC 9945654 Burriss, T. Moffatt. Strike and Hold: A Memoir of the 82nd Airborne in World War II. Washington, D.C.: Brassey's, 2000. ISBN 1-57488-258-9 OCLC 43903491 Caraccilo, Dominic J. The Ready Brigade of the 82nd Airborne in Desert Storm: A Combat Memoir by the Headquarters Company Commander. Jefferson, N.C.: McFarland, 1993. ISBN 0-89950-829-4 OCLC 27265069 Carter, Ross S. Those Devils in Baggy Pants. Cutchogue, NY: Buccaneer Books, 1996.
Chemicals abandoned at the plant continue to leak and pollute the groundwater. Whether the chemicals pose a health hazard is disputed. Contamination at the site and surrounding area was not caused by the gas leakage. The area around the plant was used as a dumping ground for hazardous chemicals and by 1982 water wells in the vicinity of the UCIL factory had to be abandoned. UCC states that "after the incident, UCIL began clean-up work at the site under the direction of Indian central and state government authorities". The work was continued from 1994 by Eveready Industries India, Limited (EIIL) who was UCIL's successor. In 1998, the Madhya Pradesh State Government, which owned and had been leasing the property to EIIL, cancelled the lease, took over the facility and assumed all accountability for the site, including the completion of any remediation. UCC's laboratory tests in 1989 revealed that soil and water samples collected from near the factory were toxic to fish. Twenty-one areas inside the plant were reported to be highly polluted. In 1991 the municipal authorities declared that water from over 100 wells was hazardous for health if used for drinking. In 1994 it was reported that 21% of the factory premises were seriously contaminated with chemicals. Beginning in 1999, studies made by Greenpeace and others from soil, groundwater, well water and vegetables from the residential areas around UCIL and from the UCIL factory area show contamination with a range of toxic heavy metals and chemical compounds.
Sources: en.wikipedia.org
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.
The solid is generally kept cold, dry, and protected from light. Solutions are often frozen in single-use aliquots to reduce repeated freeze-thaw cycles.
It indicates a material sold for laboratory study, not for human use. The label does not guarantee pharmaceutical purity, sterility, or regulatory approval.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.